Atossa Therapeutics (ATOS) appointed Mark Daniel as CFO. Daniel is a senior finance leader with more than 25 years of experience , having overseen weekly revenue forecasting in partnership with commercial leadership, managed operating expense budgets exceeding $200M, implemented and certified Sarbanes-Oxley controls, and led programs delivering over $50M in cost savings. Daniel also managed a $400M cash and investments portfolio and helped execute nearly $1B in equity, convertible debt, and credit transactions across varying market conditions.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATOS:
- Atossa Therapeutics advances global patent strategy for Z-Endoxifen
- Atossa Therapeutics management to meet virtually with Craig-Hallum
- Strategic Adjustments and Promising Data Bolster Atossa Therapeutics’ Buy Rating
- Promising Potential of Atossa Therapeutics’ Endoxifen in Metastatic Breast Cancer Treatment
- Atossa Therapeutics Releases Updated Corporate Presentation